Heart Failure

Your daily dose of clinical news you may have missed.

SGLT-2 inhibitors were found to consistently reduce risk of CV mortality and HF events in a meta-analysis including 90 000 high-risk patients with T2D, CKD, and/or HF.

Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.

Your daily dose of clinical news you may have missed.

In a new study of adults with T2D and/or HF, those with higher prescription copayments were less likely to achieve 1-year adherence to GLP1-RA and SGLT2i therapies.

The novel co-inhibitor of sodium glucose cotransporter-1/2 proteins will be available by the end of June 2023, according to Lexicon Pharmaceuticals.

“Patients with COPD who have AMI are less aggressively treated than those without COPD," leading to higher in-hospital mortality and long-term mortality,” wrote authors.

The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with HFmrEF or HFpEF.

Studies on supervised exercise training in patients with chronic, stable HFpEF suggest substantial improvements in exercise capacity and QoL that may surpass those seen with medication.

ACC 2023. In an analysis of patients with heart failure, never having been married was associated with worse survival compared with having been married.

Your daily dose of clinical news you may have missed.

After hospital discharge for heart failure, adults treated with either furosemide or torsemide had similar mortality rates, according to results from the TRANSFORM-HF clinical trial.

Patient Care Guideline Toplines summarize newly revised and updated clinical recommendations from professional societies for convenient, at-a-glance review.

Approved in 2020 as Nexletol, bempedoic acid as the first ATP citrate lyase inhibitor and oral non-statin therapy to meet the MACE-4 primary endpoint.

In the SOLOIST-WHF trial, risk for HF readmission and CV death were reduced by more than 50% at 30- and 90-days after hospital discharge.

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.

SGLT-2 inhibitors and drugs to treat HFrEF were compared for efficacy in patients with HF with LVEF ≥40%.

Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.

A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.

Physical performance scores used as a proxy for function in adults aged >65 years improved CVD risk prediction beyond traditional risk factors, study authors report.

A diagnosis of NAFLD was associated with a 50% greater risk of new-onset heart failure in a meta-analysis comprised of more than 11 million individuals.

Patients with HFpEF who significantly restrict salt consumption have increased risk for cardiovascular and HF events and HF hospitalization, according to new research.

Chronic kidney disease is underdiagnosed and undertreated across major Western countries, according to findings of the new CaReMe CKD study.

ADA 2022: In a real-world study of nearly half a million adults with T2D followed for 5 years, the SGLT-2 inhibitor surpassed both other classes used in routine clinical care.

Among more than 3000 participants with prediabetes, neither metformin or lifestyle change reduced risk for CV events over 21 years according to Diabetes Prevention Program Outcomes Study investigators.

High-level results show the trial met its composite primary endpoint, lowering risk of CV death or worsening disease in patients with HFmrEF/HFpEF.

PCPs and internists accounted nationally for 57% of SGLT2i and 52% of GLP1RA prescriptions in 2020, more than any other specialty, according to new research.

The cardiac myosin inhibitor is the only treatment that targets the pathophysiology of the disease, improving patient function and symptoms.

Persons with ASCVD who quit smoking could gain 5 more years of life--similar to the outcome of intensive medical treatment while continuing to smoke.

In patients with type 2 diabetes and chronic kidney disease with and without history of CVD, finerenone was associated with improved CV and kidney outcomes.